Dai­ichi Sankyo signs agree­ment with Lead Dis­cov­ery Cen­tre

BioSpectrum (Asia) - - Company News -

Dai­ichi Sankyo, Max Planck In­no­va­tion and the Lead Dis­cov­ery Cen­tre have signed an agree­ment pro­vid­ing Dai­ichi Sankyo with the op­tion to re­ceive the ex­clu­sive rights to a new lead com­pound for the treat­ment of can­cer to be dis­cov­ered and de­vel­oped at the Lead Dis­cov­ery Cen­tre.

This new part­ner­ship builds on bi­ol­ogy in­sights in the field of tran­scrip­tional reg­u­la­tion from the work of Prof.

Matthias Geyer at the Max Planck In­sti­tute of Molec­u­lar Phys­i­ol­ogy in Dort­mund and the Re­search Cen­tre cae­sar (Cen­tre of Ad­vanced Euro­pean Stud­ies and Re­search) in Bonn, Ger­many. Com­bined with the Lead Dis­cov­ery Cen­tre’s strong drug dis­cov­ery ex­per­tise in the de­sign of highly se­lec­tive ki­nase in­hibitors, Dai­ichi Sankyo,

Max Planck re­searchers and the Lead Dis­cov­ery Cen­tre will now closely co­op­er­ate to fur­ther op­ti­mize these novel com­pounds that tar­get can­cer cell tran­scrip­tion and pro­lif­er­a­tion. Dai­ichi Sankyo to­gether with the Max Planck So­ci­ety, sup­ported by Max Planck Foun­da­tion, will jointly fund the re­spec­tive drug dis­cov­ery ef­forts at the Lead Dis­cov­ery Cen­tre.

The agree­ment in­cludes an up­front pay­ment as well as devel­op­ment and sales mile­stones plus roy­al­ties. The li­cens­ing rev­enues will be shared be­tween Max Planck So­ci­ety, the Lead Dis­cov­ery Cen­tre and all con­tribut­ing re­searchers and in­sti­tu­tions.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.